Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566112 | 0.92 | LGMN (0.44) | LGMNMAPTPIK3CAMTORPTPN11 | |
| SCHEMBL15783989 | 0.81 | CYP11B1 (0.54) | LGMNMAPTALDH1A1GSK3AGSK3B | |
| SCHEMBL15783934 | 0.80 | MAPT (0.56) | MAPTPTPN11ALDH1A1GSK3AGSK3B | |
| SCHEMBL16702875 | 0.80 | MAPT (0.52) | MAPTGSK3AGSK3B | |
| SCHEMBL14881721 | 0.79 | MAPT (0.55) | LGMNMAPTPIK3CAALDH1A1SMN1; SMN2 | |
| SCHEMBL30309939 | 0.79 | MAPT (0.55) | LGMNMAPTPIK3CAALDH1A1SMN1; SMN2 | |
| SCHEMBL15784034 | 0.79 | CYP11B1 (0.51) | MAPTPIK3CAMTORGSK3AGSK3B | |
| SCHEMBL15783994 | 0.78 | MAPT (0.55) | MAPTPIK3CAMTORPTPN11ALDH1A1 | |
| SCHEMBL15786789 | 0.78 | MAPT (0.55) | MAPTPTPN11 | |
| SCHEMBL23536222 | 0.78 | LGMN (0.58) | LGMNMAPTPTPN11ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| EP-4534538-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3808749-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES | VERTEX PHARMA (US) | 2023-03-08 | — | — | EP | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| WO-2014089379-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089379-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | LGMN 3086/4885MAPT 2470/4885PIK3CA 97/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | LGMN 3402/4885MAPT 4106/4885PIK3CA 153/4885 |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | LGMN 3143/4885MAPT 2585/4885PIK3CA 102/4885 |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, CHEK1 | LGMN 3086/4885MAPT 2470/4885PIK3CA 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.